Page 24 - Read Online

Page 274 Arroyo Seguí et al. J Transl Genet Genom 2020;4:263-77 I http://dx.doi.org/10.20517/jtgg.2020.35

Not available Not available CYP3A4*1B: Level 3 CYP3A4*1B: Level 3 CYP3A5: not available

[55] [60] [65] [67]

No significant association was found for the OPRK1 variant For SLC6A3/DAT1, presence of the 11-repeat allele was significantly associated with the responder status. Presence of the 10-repeat allele was higher in non-responders (64.9%), but no significant association was observed No significant association found As a CYP3A4*1B carrier, the patient was classified as an ultrarapid metabolizer (UM). Patient needed a dose of 32 mg to maintain abstine

rs1051660 3’ UTR VNTR 5 TaqI A polymorphism (A1) *1/*1B N/A (phenotype) 1 Level of evidence based on Pharmacogenomics Knowledgebase (PharmGKB) criteria 69 and current as of May 31, 2020. Available at https:/ /www.pharmgkb.org/. 1A: Annotation for a variant- drug combination in a CPIC or medical society-endorsed PGx guideline, or implemented at a PGRN site or in another major health system. 1B: Annotation for a variant-drug combination where the

SLC6A3/DAT1

OPRK1 DRD2 CYP3A4 CYP3A4 CYP3A5

Responders vs. non- responders 4 Treatment outcomes 6 , withdrawal incidence 7 , direct opioid effects 8 Urine drug screens for unauthorized substances Dosing (SOC vs. PGx) 9 , withdrawal incidence, urine drug screens

Western European (n = 107, 81% males) Australian (n = 25, 68% females) (88% European ancestry) African American (n = 1 male) African American (n = 111, 76% males) (PGx)